<DOC>
	<DOCNO>NCT02744820</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ( PK ) multiple oral dos GMC-252-L-Lysine salt ( GMC-252 ) healthy subject type 2 diabetic . The secondary objective explore effect multiple oral dos GMC-252 pharmacodynamic ( PD ) parameter type 2 diabetic .</brief_summary>
	<brief_title>Multiple Ascending Dose Study GMC-252-L-Lys Salt Healthy Subjects Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Criteria Part 1 ( Healthy Subjects ) Part 2 ( Type 2 Diabetic Patients ) : 1 . Diet : Able eat standard food , vegetarian . 2 . Compliance : Understands willing , able likely comply study procedure restriction . 3 . Consent : Demonstrates understand study give sign , voluntary write informed consent . 4 . Have know hypersensitivity diflunisal , NAC NSAIDs . 5 . No history blood disease include limited clinically significant platelet disease coagulation abnormality . 6 . No clinically relevant gastrointestinal disease . 7 . Have estimate creatinine ( CREA ) clearance &gt; 70 mL/min/surface area ( CREA clearance calculate serum CREA value use Cockroft Gault formula ) . 8 . Have history heart failure uncontrolled hypertension know clinically significant cardiovascular disease . 9 . Have history bronchial asthma 'Aspirin Triad ' ( chronic rhinosinusitis polyp , severe asthma intolerance aspirin NSAIDs ) . 10 . Have clinically significant abnormality liver test entry study . 11 . A negative urinary drug abuse screen , determine within 28 day first dose ( N.B . positive alcohol result may repeat discretion Investigator ) . 12 . Negative human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( Hep B ) hepatitis C virus antibody ( Hep C ) result . 13 . No clinically significant abnormality 12lead ECG determine within 28 day first dose . 14 . No history clinically significant renal disease food intolerance . 15 . Willing use 2 effective method contraception i.e . establish method contraception + condom , applicable ( unless anatomically sterile abstain sexual intercourse line prefer usual lifestyle subject ) Day 1 3 month afterwards . Additional Criteria Part 1 ( Healthy Subjects ) : 1 . Healthy male age 18 55 inclusive . 2 . Body mass index ( BMI ) within range 1830 kg/m2 inclusive . 3 . NonSmokers ( include ecigarettes ) abstain smoke least 6 month . Additional Criteria Part 2 ( Type 2 Diabetic Patients ) : 1 . Males age 18 65 inclusive . BMI within range 1838 kg/m2 inclusive . 2 . Diagnosis T2DM accord World Health Organization criterion . 3 . HbA1c 7.0 % 12.0 % inclusive . 4 . Currently treat metformin stable treatment regimen 3 month prior Screening Visit , receive antidiabetic medication . Allowed medication study include metformin , statin ( 3hydroxy3methylglutarylcoenzyme A ( HMG CoA ) reductase inhibitor ) , paracetamol 3 g/day , low dos aspirin antihypertensive drug dos change 3 month start screen . Other allowed medication approve PI Sponsor patient enrol . Diflunisal ( test drug component ) may decrease antihypertensive activityof many currently use antihypertensive medication , βblockers , alpha ( α ) blocker , loop diuretic , angiotensin convert enzyme ( ACE inhibitor ) , angiotensin 2 receptor blocker , calcium channel blocker . Therefore , patient current stable antihypertensive medication subject close monitoring blood pressure throughout study . 5 . Stable dietary habit regimen treatment concomitant diseases 1 month prior Screening Visit . 6 . Subject able willing undergo oral glucose tolerance test ( OGTT ) . Exclusion Criteria Part 1 ( Healthy Subjects ) Part 2 ( Type 2 Diabetic Patients ) : 1 . A clinically significant history previous allergy / sensitivity GMC252 component , NAC diflunisal . 2 . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . 3 . Participation New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month . ( N.B . washout period study define period time elapse last dose previous study first dose next study ) . 4 . Donation 450 mL blood within previous 3 month . 5 . A clinically significant history drug , alcohol substance abuse past 2 year . Additional Criteria Part 1 ( Healthy Subjects ) : 1 . A clinically significant history gastrointestinal disorder likely influence drug absorption . 2 . Receipt regular medication within 28days first dose may impact safety objective study ( Investigator 's discretion ) . 3 . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . Additional Criteria Part 2 ( Type 2 Diabetic Patients ) : 1 . Diagnosis/General Health : Diabetic autonomic sensory neuropathy include gastroparesis , diabetic nephropathy untreated active proliferative retinopathy . Clinically significant abnormality laboratory evaluation ( include clinical biochemistry , haematology urinalysis ) opinion Investigator . 2 . Diseases : Uncontrolled hypertension ( blood pressure ≥ 160/100 mmHg ) , severe unstable angina , coronary insufficiency , congestive heart failure , clinically significant ( opinion Investigator ) renal hepatic disease . Previous gastric intestinal surgerythat might impact drug absorption . Malignancy within 5 year start study , except successfully treat local basal cell carcinoma Current relevant previous history , clinically significant psychiatric illness . 3 . Medications : Current use insulin previous use insulin part clinical trial associate surgical procedure acute illness 7 day . Use anti diabetic medication metformin 3 month prior study entry . Current use anticoagulant drug e.g . warfarin , heparin . Prior use ( within 48 h dose ) drug could alter gastric motility ( domperidone , cyclizine , metoclopramide , prochlorperazine ) , cholestyramine .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>